Lumira

Last July, Angelini Pharma and Lumira Ventures announced the launch of Angelini Lumira Biosciences Fund (ALBF). The fund, managed by Lumira Ventures, a North American venture capital firm and leader in the life sciences field, was established with the goal of investing in early-stage companies in Canada and the United States that are developing pharmaceutical therapies for central nervous system disorders and rare diseases.